文献速递牙体牙髓病

RANKL 触发 Treg 介导的免疫调节在感染性根尖周骨溶解中

RANKL Triggers Treg-Mediated Immunoregulation in Inflammatory Osteolysis.
PubMed 文献 · J Dent Res · 2018-03-02

研究用小鼠感染性根尖周病变模型,给予持续或暂时性抗 RANKL 抑制,分析病变结局与宿主反应。抗 RANKL 虽阻止骨丧失,但干扰了未处理组自然出现的免疫调节,表现为持续的促炎反应和 Treg 迁移减少。早期给药损害免疫调节,晚期给药不干扰已建立的免疫调节;过继转移 CD4+FOXp3+ Treg 可恢复免疫调节能力并防止停药后病变复发。

要点

  • 抗 RANKL 抑制骨丧失但干扰 Treg 介导的免疫调节,导致持续促炎反应。
  • 抗 RANKL 的免疫干扰仅见于疾病早期,晚期给药不影响已建立的免疫调节。
  • 过继转移 CD4+FOXp3+ Treg 可恢复免疫调节并防止停药后病变复发。

核心结论

  • RANKL 抑制虽有效限制根尖周骨丧失,但通过干扰 Treg 活性促进持续的宿主炎症反应,提示 RANKL 参与免疫调节。

研究设计与样本

  • 采用小鼠感染性炎症性根尖周病变模型,分为持续或暂时性抗 RANKL 抑制组,分析病变结局及多项宿主反应参数。

主要发现

  • 抗 RANKL 给药导致骨丧失停止,但干扰了未处理组观察到的病变自然免疫调节。
  • RANKL 抑制引起持续的促炎反应、持续高水平的促炎和效应 CD4 反应、Treg 迁移减少以及 Treg 相关细胞因子 IL-10 和 TGFb 水平降低。
  • 抗 RANKL 阻断仅在疾病早期损害免疫调节过程,晚期给药不干扰已建立的免疫调节。
  • RANKL 抑制导致的免疫调节受损表现为体内迟发型超敏反应增强和体外针对感染细菌的 T 细胞增殖增加,模拟 Treg 抑制效应。
  • 过继转移 CD4+FOXp3+ Treg 至接受抗 RANKL 治疗的小鼠可恢复免疫调节能力、减轻病变炎症反应、重建体内外正常 T 细胞反应并防止停药后病变复发。

关键数值与推荐

  • 抗 RANKL 给药导致骨丧失停止但干扰自然免疫调节;早期给药损害免疫调节,晚期给药不干扰已建立的免疫调节。
  • RANKL 抑制后 Treg 迁移减少,IL-10 和 TGFb 水平降低;过继转移 CD4+FOXp3+ Treg 可恢复免疫调节能力。

临床怎么用

  • 提示 RANKL 抑制在控制根尖周骨丧失的同时可能削弱 Treg 介导的免疫调节,需关注早期用药对免疫应答的干扰。
  • 过继转移 CD4+FOXp3+ Treg 可能作为恢复免疫调节、防止停药后病变复发的潜在策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The chronic inflammatory immune response triggered by the infection of the tooth root canal system results in the local upregulation of RANKL, resulting in periapical bone loss. While RANKL has a well-characterized role in the control of bone homeostasis/pathology, it can play important roles in the regulation of the immune system, although its possible immunoregulatory role in infectious inflammatory osteolytic conditions remains largely unknown. Here, we used a mouse model of infectious inflammatory periapical lesions subjected to continuous or transitory anti-RANKL inhibition, followed by the analysis of lesion outcome and multiple host response parameters. Anti-RANKL administration resulted in arrest of bone loss but interfered in the natural immunoregulation of the lesions observed in the untreated group. RANKL inhibition resulted in an unremitting proinflammatory response, persistent high proinflammatory and effector CD4 response, decreased regulatory T-cell (Treg) migration, and lower levels of Treg-related cytokines IL-10 and TGFb. Anti-RANKL blockade impaired the immunoregulatory process only in early disease stages, while the late administration of anti-RANKL did not interfere with the stablished immunoregulation. The impaired immunoregulation due to RANKL inhibition is characterized by increased delayed-type hypersensitivity in vivo and T-cell proliferation in vitro to the infecting bacteria, which mimic the effects of Treg inhibition, reinforcing a possible influence of RANKL on Treg-mediated suppressive response. The adoptive transfer of CD4+FOXp3+ Tregs to mice receiving anti-RANKL therapy restored the immunoregulatory capacity, attenuating the inflammatory response in the lesions, reestablishing normal T-cell response in vivo and in vitro, and preventing lesion relapse upon anti-RANKL therapy cessation. Therefore, while RANKL inhibition efficiently limited the periapical bone loss, it promoted an unremitting host inflammatory response by interfering with Treg activity, suggesting that this classic osteoclastogenic mediator plays a role in immunoregulation.

来源:J Dent Res,查看原文。版权归原作者所有。

引用

  1. Francisconi CF, Vieira AE, Azevedo MCS, et al. RANKL Triggers Treg-Mediated Immunoregulation in Inflammatory Osteolysis. J Dent Res. 2018. PMID: 29499125. doi:10.1177/0022034518759302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。